4 days ago
Dr. Lal PathLabs boots genomics capabilities with Illumina's NovaSeq™ X Series
By Aman Shukla Published on June 25, 2025, 11:39 IST
Dr. Lal PathLabs Limited (DLPL), one of India's most trusted names in diagnostics, has taken a major step forward in genomics by adding the advanced NovaSeq™ X Series from Illumina to its dedicated genomics unit, Genevolve.
This cutting-edge technology allows DLPL to deliver faster and more accurate results in genetic research. The NovaSeq™ X system, powered by Illumina's XLEAP-SBS™ chemistry, offers top-notch performance with high speed, accuracy, and sustainability. In fact, the NovaSeq X Plus can handle over 20,000 whole genomes per year—twice as much as earlier models.
Genevolve, launched in 2019, has quickly made a name for itself as a leader in DNA-based diagnostics and next-generation sequencing (NGS). With the new Illumina platform onboard, DLPL is now even better equipped to offer quick, AI-driven insights that can support smarter healthcare decisions.
'With the addition of Illumina's NovaSeq X Series, we are taking another step forward in driving innovation and scientific excellence,' said Shankha Banerjee, CEO, Dr. Lal PathLabs Limited. 'This investment allows us to broaden our capabilities and contribute meaningfully to India's evolving genomics landscape.'
Looking ahead, Dr. Lal PathLabs and Illumina plan to work closely with India's medical and research communities to promote the use of genomics in healthcare, helping unlock new possibilities in personalized medicine.
Ahmedabad Plane Crash
Aman Shukla is a post-graduate in mass communication . A media enthusiast who has a strong hold on communication ,content writing and copy writing. Aman is currently working as journalist at
